请使用支持JavaScript的浏览器!
主营:分子类,蛋白类,抗体类,生化类试剂
℡ 4000-520-616
℡ 4000-520-616
CellGenix/CellGenix® rh TNF-α/50µg/1406-050
产品编号:1406-050
市  场 价:¥0.00
场      地:美国(厂家直采)
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:待定
品      牌: CellGenix
公      司:CellGenix
公司分类:
CellGenix/CellGenix® rh TNF-α/50µg/1406-050
商品介绍

Technical Details

Source
Expressed in E. coli
Description

Human TNF-α, accession # P01375, Val77-Leu233

Formulation

Lyophilized from 200 µl of a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5

Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP.

 PreclinicalGMP
Molecular weight17.5 kDa17.5 kDa
Purity≥ 95% as determined by SDS-PAGE≥ 97% as determined by SDS-PAGE
Activity≥ 20 x 106 IU/mg, calibrated against NIBSC #88/786 Measured in a cell cytotoxicity assay using a TNF-α-sensitive cell line, L929

20 – 80 x 106 IU/mg, calibrated against NIBSC #88/786 Measured in a cell cytotoxicity assay using a TNF-α-sensitive cell line, L929

Batch specific activity on CoA

Endotoxin level< 1000 EU/mg≤ 50 EU/mg
Intended useIntended for preclinical ex vivo use. Not intended for therapeutic use.Intended for clinical ex vivo use. Not intended for human in vivo application.

Handling Instructions

Reconstitution

Recommended in sterile water to a final concentration of 250 µg/ml.

Shipment

Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.

Expiry

≥ 6 months from date of shipping. Please refer to Certificate of Analysis for the exact expiry date.

Storage & Stability

Store lyophilized cytokine at -20°C to -80°C.

Store a 100 µg/ml reconstituted cytokine solution:

• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container. 

• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.

Avoid repeated freeze/thaw cycles.

Documents

  • Data Sheet: GMP or Preclinical
  • Material Safety Data Sheet: MSDS
  • Certificate of Analysis
  • Technote: ADCF and Serum-free Policy
  • Technote: Batch-to-Batch Consistency of CellGenix® GMP Cytokines
  • Technote: Stability of CellGenix® GMP Cytokines after Reconstitution
  • Technote: Shipment of CellGenix® Preclinical and GMP Cytokines at Ambient Temperatures
  • Technote: CellGenix® rh Cytokines - Preclinical vs GMP
  • More information under Resources

Data

CellGenix GMP rh TNF-α has an activity of 20 – 80 × 106 IU/mg

The activity of GMP rh TNF-α was measured in a cell cytotoxicity assay using L929 cells. It was calibrated against NIBSC #88/786.

You can find the batch specific activity on the certificate of analysis (CoA).

Regulatory Support

We offer the following to assist you with your regulatory approval process:

  • Comprehensive documentation (e.g. DMFs, Regulatory Support Files, Certificates of Origin)
  • Outstanding QC support (e.g. extensive stability data)
  • The possibility to audit our production site
  • Detailed batch specific test results on our Certificates of Analysis
  • Change notifications prior to relevant changes

Customized solutions can be provided to meet special compliance needs. Contact our Regulatory Support Team for all your regulatory requests & questions:

Phone:     +49 761 88 88 9-302 Email:      regulatorysupport@cellgenix.com

In order to stay up-to-date and help improve regulatory guidance we are actively involved in many of the regulatory initiatives and discussions. We were amongst others actively involved in the discussions for the setup of Ph. Eur. General Chapter 5.2.12 and the ISO Technical Standard 20399.

Regulatory Resources

  • TSE certificate (available on request)
  • Regulatory Support File (available on request)
  • Request a DMF Letter of Authorization (USA only)

Publications

  • A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanomaPoschke, I. et al., 2014, Cancer Immunology, Immunotherapy
  • Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapyHansen, M. et al., 2013, Vaccine
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeDanull, J. et al., 2013, The Journal of Clinical Investigation
  • In-chip fabrication of free-form 3D constructs for directed cell migration analysisOlsen, MH. et al., 2013, Lab on a Chip
  • Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastomaVik-Mo, EO. et al., 2013, Cancer Immunology Immunotherapy
  • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysatesPellegatta, S. et al., 2013, Oncoimmunology
  • A phase II study evaluating the safety and efficacy of an adenovirus-DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinomaChia, WK. et al., 2012, Annals of Oncology
  • Myeloid-derived suppressor cells impair the quality of dendritic cell vaccinesPoschke, I. et al., 2012, Cancer Immunology, Immunotherapy
  • Is Anticancer Vaccine Possible: Experimental Application of Produced mRNA Transfected Dendritic Cells Derived from Enriched CD34+ Blood Progenitor CellsLazarova, P. et al., 2012, Immunodeficiency, Chapter 3
  • Dendritic cell-based vaccination of patients with advanced melanoma: update of clinical outcomeRidolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patientsLesterhuis, WJ. et al., 2010, Anticancer Research
  • Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcomeVenanzi, FM. et al., 2010, Cancer, Immunology, Immunotherapy
  • Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trialTrepiakas, R. et al., 2010, Cytotherapy
品牌介绍

CellGenix质量


凭借超过25年的经验,我们是GMP制造细胞和基因治疗领域原材料的专家。

CellGenix是欧洲第一家获得用于治疗性细胞加工的GMP制造授权的公司。自己作为ATMP制造商,使我们获得了深入的细胞培养知识和卓越的法规专业知识。凭借这种独特的背景,我们了解您在产品开发和法规批准过程中面临的高要求。我们可以通过提供专业的技术和法规支持来帮助您简化原材料的鉴定和验证工作。 


自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔